Charles River Laboratories International, Inc. and Autolomous announced the launch of Apollo Orchestrate on October 6, 2026, a new capability within Charles River's Apollo platform that connects and digitizes laboratory execution, built on Autolomous' autoloMATE digital Laboratory Execution System (LES). The launch is part of Charles River's strategic commitment to modernization and digitization, and marks a significant milestone in its broader, ongoing transition toward digital, connected, compliant, and scalable laboratory execution.
The deployment brings Apollo Orchestrate's electronic execution record and workflow-automation capabilities, powered by Autolomous’ autoloMATE, to Charles River Biologics Testing Solutions sites across North America and Europe, supporting quality control (QC) testing within the Good Manufacturing Practice (GMP) setting. Apollo Orchestrate connects Charles River's laboratory systems, including Apollo and LabWare LIMS, supporting digital traceability from sample submission through execution to release.
"Aligned with our modernization strategy, it is crucial that we evolve quickly to enhance efficiencies and ensure medicines reach patients swiftly and safely," said Kerstin Dolph, Corporate Senior Vice President of Global Manufacturing, Charles River. "The launch of Apollo Orchestrate, built on Autolomous' autoloMATE platform, will increase efficiency while providing greater transparency and collaboration for our clients, both of which are key to our strategic goals."
This marks an important step in Charles River's development of an integrated digital laboratory ecosystem, enabling a more seamless workflow focused on getting results to the client in a rapid and accurate manner.
Enabled by autoloMATE’s LES, Apollo Orchestrate connects sample submission, laboratory execution, and review into one digital workflow and shifts records from paper to digital, with a path to greater client visibility over time. It enhances efficiency by minimizing manual processes, improving data accuracy, accelerating execution and review, and allowing technical and QA teams to spend less time on administrative review and more on scientific, quality, and client-focused work. Initial deployment within the GMP setting for QC testing will establish a standardized, scalable operating model for expansion across Biologics Testing Solutions sites following the initial go-live.
"Biological testing proves that a medicine is safe, effective, and ready for patients, but data collection and management across fragmented, often manual and paper-based systems from R&D to commercial release create unnecessary delays for patients, opportunities for errors, audit risks, and lost revenue," said Alexander Seyf, CEO of Autolomous. "We designed autoloMATE to enable life sciences companies to connect that data directly into an integrated, digitized workflow and increase speed, accuracy, and cost-effectiveness."
